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Payers are a major stakeholder in any considerations and initiatives concerning adaptive
licensing of new medicinal products, also referred to as Medicines Adaptive Pathways
to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny,
especially with regard to the definition of unmet need. Conditional approval pathways
already exist for new medicines for seriously debilitating or life-threatening diseases and
only a limited number of new medicines are innovative. Secondly, MAPPs will result in
new medicines on the market with limited evidence about their effectiveness and safety.
Additional data are to be collected after approval. Consequently, adaptive pathways may
increase the risk of exposing patients to ineffective or unsafe medicines. We have already
seen medicines approved conventionally that subsequently proved ineffective or unsafe
amongst a wider, more co-morbid population as well as medicines that could have been
considered for approval under MAPPs but subsequently proved ineffective or unsafe in
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Phase III trials and were never licensed. Thirdly, MAPPs also put high demands on payers.
Routine collection of patient level data is difficult with high transaction costs. It is not clear
who will fund these. Other challenges for payers include shifts in the risk governance
framework, implications for evaluation and HTA, increased complexity of setting prices,
difficulty with ensuring equity in the allocation of resources, definition of responsibility
and liability and implementation of stratified use. Exit strategies also need to be agreed in
advance, including price reductions, rebates, or reimbursement withdrawals when price
premiums are not justified. These issues and concerns will be discussed in detail including
potential ways forward.
Keywords: EMA, adaptive pathways, payers, marketing authorization, Europe
INTRODUCTION
In most European countries, healthcare is seen as a public good,
inasmuch as universal healthcare is a stated or accomplished
goal—be it through a government-funded system or mandatory
health insurance1. Pharmaceuticals are a major component of
healthcare, and their provision increasingly challenges healthcare
systems2 (Malmstrom et al., 2013). Consequently, it is no
surprise that those responsible for payment or reimbursement
of medicines, and their advisors (collectively referred to as
“payers”), carefully observe developments at the European
level including initiatives of the European Medicines Agency
(EMA). Since the provision of healthcare is subject to the
principle of solidarity and therefore a national issue, any projects
involving access to medicines from the moment of marketing
authorization, especially for new premium priced medicines, are
subject to particular scrutiny from their perspective (Godman
et al., 2015; Matusewicz et al., 2015).
EMA started a pilot on adaptive licensing, later renamed to
adaptive pathways, in March 2014. The rationale for MAPPs, and
the project itself, have been described in scientific publications
under the participation of EMA scientific officers as well as on
EMA’s website (Eichler et al., 2015)3. Briefly, adaptive pathways
should be a holistic approach to medicines’ approval, based on
the premise that approval can be done iteratively, i.e., a medicine
can at first be either approved for a small group of patients, if
there is enough compelling evidence, and later approved for a
larger patient group based on the evidence collected after the
approval for the initial group. Alternatively, a medicine could
be approved on the basis of preliminary clinical data, such as
surrogate endpoints, e.g., biomarkers or response rates, which
would ultimately need to be verified with the help of clinical
data reflecting actual patient benefit such as increased length
1Official Journal of the European Union. Council Conclusions on Common values
and principles in European Union Health Systems (2006/C 146/01). Available
at URL: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:
52006XG0622(01)&from=EN.
2European Council. Council conclusions on strengthening the balance in the
pharmaceutical systems in the EU and its Member States. Available at URL: http://
www.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-balance-
pharmaceutical-system/.
3EMA Adaptive Pathways Reply to Prof. Silvio Garattini, Peter C. Gøtzsche, Tom
Jefferson, Joan-Ramon Laporte, Joel Lexchin, Donald W. Light, Martin McKee,
Jean-Louis Montastruc, Sir Richard Thompson. Available at URL: http://www.
ema.europa.eu/docs/en_GB/document_library/Other/2016/06/WC500208968.
pdf.
of survival in patients with advanced cancer or a reduction in
cardiac events (Davis et al., 2016). Adaptive pathways are not
meant to be a new route of approval for medicines, but to make
use of existing approval tools, in particular conditional marketing
authorization4.
To support MAPPs, IMI (the Innovative Medicines Initiative)
initiated ADAPT SMART as an enabling and coordination
platform for MAPPs5,6. IMI is a joint initiative between the
European Union and the European Pharmaceutical Industry
Association—EFPIA5. However, theMAPPs approach is evolving
and it is currently controversial. We not only see criticism from
independent scientists and organizations7 (Davis et al., 2016;
Hawkes, 2016a,b; EPHA8; IQWiG9), but also publications from
the EMA sphere contradicting official EMA statements (Eichler
et al., 2012; 2015).
In August 2016, the EMA published a final report on the
Adaptive Pathways pilot4. All discussions within this pilot were
confidential so neither the precise contents of these discussions,
nor all the companies involved, are publicly known. The
report describes the experience of selecting seven appropriate
projects from 62 initial applications and of six multi-stakeholder
consultations on the development pathway. It emphasizes the
feasibility and usefulness of jointly agreeing on a data generation
plan which meets the needs of regulators and health technology
assessors. However, the report acknowledges the limitations of
MAPPs - key unsolved issues of “real-life” data generation,
prescriptions management, managed entry agreements (MEAs),
4EMA Final report on the adaptive pathways pilot. Available at URL: http://www.
ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.
pdf.
5ADAPTSMART Accelerated Development of Appropriate Patient Therapies—a
Sustainable, Multistakeholder Approach from Research to Treatment-outcomes.
Available at URL: http://adaptsmart.eu/.
6ADAPT-SMART Project Overview. Available at URL: http://adaptsmart.eu/wp-
content/uploads/2015/09/ProjectOverview-IMI2-ADAPTSMART.pdf.
7Joint briefing paper “Adaptive licensing” or “adaptive pathways”: Deregulation
under the guise of earlier access. Available at URL: http://ec.europa.eu/health/files/
committee/stamp/2015-10_stamp3/3c_prescrire_position_paper.pdf.
8EPHA Briefing:Will fast-tracking medicines improve affordability? Letter to Prof.
Rasi and Dr Eichler. Available at URL: http://epha.org/wp-content/uploads/2016/
05/Will-fast-tracking-for-new-medicines-improve-affordability-formatted-5.
pdf.
9Adaptive pathways: EMA still leaves open questions unanswered. Current EMA
report on the pilot project again documents perplexity regarding the use of “real
world data”. Available at URL: https://www.iqwig.de/en/press/press-releases/
press-releases/adaptive-pathways-ema-still-leaves-open-questions-unanswered.
7492.html.
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and how to leave the adaptive pathway if this becomes
necessary. The report also highlights the need to further
address the involvement of patients, healthcare professionals and
payers.
These developments and suggestions are in addition to the
PRIME project, another new initiative from the EMA, to foster
research on and development of medicines that have the potential
to address an unmet medical need10.
Unlike other goods, medicinal products need to obtain
a regulatory approval (marketing authorization) before being
placed on the market. This is justified by the fact that medicinal
products inevitably carry risks for patients and the general
population. Consequently, a special need for public protection
through a risk/benefit assessment is universally acknowledged.
The current marketing authorization procedure emerged as a
response to a number of disasters such as sulfanilamide or
thalidomide (Contergan R©)7, (Banzi et al., 2015). The European
regulatory system has been built to protect public health and to
preserve the confidence of patients and the medical professions
that, properly prescribed, the benefit of every authorized
medicine outweighs its risks.
The introduction of MAPPs is being undertaken under
the current legal framework of the Community system for
authorization of medicinal products [Commission Regulation
(EC) No 726/2004 and Commission Regulation (EC) No
507/2006]. Procedures other than the standard authorization
procedures such as conditional approval (Banzi et al., 2015)
should offer the same risk governance and level of public health
protection as standard procedures. Lowering the standards for
risk governance and marketing authorization could be in breach
of the Treaties and put patients at risk, especially given the many
recent examples where observational studies have suggested a
treatment benefit only to be overturned by RCTs (Davis et al.,
2016).
This paper explains the concerns of payers regarding the
MAPPs initiative. These build on the concerns of others (ISDB,
2016) and revolve around the scope of the initiative, its
execution, and its consequences for payers—and, ultimately,
European society, meaning patients and those who contribute
to the financing of healthcare. It also discusses possible ways
forward.
AREAS OF CONCERN
Scope and Rationale for
MAPPs—Justification of the Concept for
Adaptive Pathways
The EMA final report on adaptive pathways pilot describes
MAPPs as an iterative development plan that will initially
target a well-defined group of patients that is likely to benefit
most from the new treatment (Davis et al., 2016, EMA4). This
is supposed to be followed by iterative phases of evidence
gathering and progressive licensing adaptations, concerning both
the authorized indication and the potential further therapeutic
10First statistics on PRIME are released. Available at URL: http://www.
ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/06/
news_detail_002541.jsp&mid=WC0b01ac058004d5c1.
uses of the medicine, to expand its use to a wider patient
population as more data becomes available. Our understanding
is that this means initial marketing authorization is to be
granted for promising populations based on phase II (or
earlier) clinical data. It implies granting marketing authorization
and, ultimately, reimbursement, based principally on surrogate
endpoints. We are aware that whilst phase II trials do not always
measure surrogate endpoints, any clinical endpoint data may be
immature.We understand this tomean that speeding up access to
newmedicines via adaptive pathways is to be achieved by putting
aside traditional phase III clinical trials in favor of post-marketing
evidence generation. This requirement is problematic since only
a very limited subset of surrogate endpoints have been validated
to date and relying on unvalidated surrogate endpoints seriously
increases uncertainty and is generally advised against (EPHA8,
Mangiapane and Velasco Garrido, 2009; Velasco Garrido and
Mangiapane, 2009; Svensson et al., 2013; Henshall et al., 2014;
Naci et al., 2015; Prasad et al., 2015; IQWiG11). Examples of
concerns include extrapolating surrogate markers in patients
with advanced solid tumors such as disease free survival to overall
survival (Tuma, 2009; Kantarjian et al., 2013; Cortazar et al., 2014;
Prasad et al., 2015).
Equity and Allocation of Public Resources
in the Light of Increased Uncertainty
Accepting such clinical and economic uncertainties can only
be justified for new medicines meant for patients with high
unmet medical need, especially those with rare diseases and
if patient-relevant outcomes cannot be explored within a
reasonable amount of time. However, “unmet medical need” is
currently not precisely defined, although attempts have been
made when assessing priority areas for new medicines (Kaplan
et al., 2013; Banzi et al., 2015). For regulators and payers to
be aligned, there needs to be a common agreed position for
unmet medical need. This definition should be based upon a
public health perspective and provide a balanced, level playing
field, and the same level of risk governance for different disease
conditions.
MAPPs suggest an initial marketing authorization for a
restricted patient population upon demonstration of a positive
benefit/risk balance. However, one has to consider that even for
seriously ill patients, being treated with a new medicine with
poorly characterised benefits, and which might only cause harm,
should not be part of everyday care. Routine treatment, unlike
testing in clinical trials, should be guided by known outcomes and
not by limited or lack of knowledge.
The extent of uncertainty which patients would have to
accept if new medicines were to be authorised earlier is
illustrated by available data. The combined success rate at
phase III and submissions is only approximately 50%. Two
thirds of terminations of new medicines are due to lack of
efficacy, more than 20% due to safety issues (Arrowsmith,
2011). This suggests that preliminary data from earlier phases
of development typically overestimate the potential benefits of
11Aussagekraft von Surrogatendpunkten in der Onkologie. 2011. Available
at URL: https://www.iqwig.de/download/A10-05_Rapid_Report_Version_1-
1_Surrogatendpunkte_in_der_Onkologie.pdf.
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a new treatment, and do not allow a robust assessment of
risks and benefits. There are also a number of examples of
new medicines that were given marketing authorization on
the basis of the regular data package but were proven to be
ineffective or unsafe when used in routine clinical care (Eichler
et al., 2011; Godman et al., 2015). The latter examples have
been used to demonstrate the possibility of foregoing some
of the current requirements for marketing authorization in
exchange for better investigation after approval in a wider
more co-morbid population likely to receive the new medicine.
However, in view of the failure rates in phase III trials,
including withdrawals due to safety concerns, this scenario is
incomplete. If promising data after phase II were sufficient
for marketing authorization, a larger number of ineffective
or unsafe medicines - often at higher prices than current
standards - would have been approved. To our knowledge, no
adequate measures to safeguard against this have been proposed
for MAPPs.
According to the EMA report on MAPPs, adaptive pathways
seek to balance timely access for patients who are likely to
benefit most from the new medicine with the need to provide
adequate evolving information on the benefits and risks of the
new medicine itself4. Publications arising from the EMA suggest
that the EMA is of the opinion that earlier access to new
medicines is necessary and that adaptive pathways are a key
way to achieve this goal. We have concerns with this belief.
This is because the number of new medicines that have been
approved by EMA has been quite stable in recent years with no
discernible decline indicating problems in the approval process12.
Consequently, we see little need to change this. Pharmaceutical
companies should as a matter of course already be seeking
ways to optimize development cycles. Lastly, the potential to
speed up market access for new medicines when there is true
unmet medical need already exists. This includes compassionate
use programs or named patient programs7 (Baird et al., 2014).
Consequently, there should be objective and scientifically valid
justifications for new measures such as adaptive pathways to
ensure protection of patients8 (Davis et al., 2016; Hawkes, 2016a).
As a result, the current rationale for MAPPs does not appear
compelling.
The Risk-Governance Framework—How
Beneficial are MAPPs?
Earlier approval, which is already in existence, has for instance
increased the number of black-box warnings and withdrawals
in the US7 (Frank et al., 2014). In addition Prescrire, an
independent drug information journal, recently assessed 22
medicines “approved conditionally” in the EU since 2006. They
believed 27% were “not acceptable,” such as medicines without
evident benefit but with potential or real disadvantages, 28% as
having “judgment reserved,” i.e., assessments reserved until better
data becomes available, 9% as “nothing new,” 18% as “possibly
helpful” and only 18% as “offering an advantage”13. There have
12EMA Annual Report 2015. Available at URL: http://www.ema.europa.eu/docs/
en_GB/document_library/Annual_report/2016/05/WC500206482.pdf.
also been concerns with five out of the six orphan medicines
receiving marketing authorisation in 2004 (Joppi et al., 2016).
Existing ways to speed up approval for marketing
authorization (like conditional or exceptional approval) already
pose problems for conducting health technology assessments
(HTAs) and implementing measures such as valuing new
medicines based on the data presented. Earlier access means
inherently less available data at the time of approval. This
lack of information impedes assessments of the therapeutic
value of new medicines and thereby decisions on value-based
pricing, exacerbated by concerns with defining terms such
as innovation (Annemans et al., 2012). This has important
implications for ever-increasing requested prices, especially
new medicines for cancer and for orphan diseases (Cohen
and Felix, 2014; Kelly and Smith, 2014; Godman et al., 2015;
Howard et al., 2015). While up to now marketing authorization
decisions and information are generally used as the baseline
for reimbursement decisions, this position will need to be
reconsidered in the framework for HTA for new medicines
subject to the MAPPs process. This will create considerable
challenges in already resource constrained healthcare
systems.
EMA noted that adaptive licensing is already happening
within the current framework as part of conditional approvals
or initial approval as last-line treatment with clinical trials for
earlier stages of disease to be completed at a later point in time7
(Banzi et al., 2015; Cerreta, 2015). Currently, these approaches
are limited to special cases such as life-threatening or seriously
debilitating diseases3. However, there are major concerns among
payers if adaptive licensing becomes the preferred approach
in the future (Eichler et al., 2015; Davis et al., 2016; Hawkes,
2016a,b). These concerns are heightened by the opinion of
some that not only immediately life-threatening diseases have an
unmet medical need, but in the end all diseases have a “treatment
window of opportunity.” “The urgency of access to promising
treatments is independent of disease dynamics: for every year
without access, the window will shut on one annual cohort of
patients, whether the window is short or long” (Eichler et al.,
2015). This would open the possibility of adaptive pathways being
considered for all new medicines across populations. Due to the
inherent uncertainty of earlier access, greater risks to patients
are expected to arise from this uncertainty. Payers and their
advisers are concerned that this paradigm shift in the regulatory
process could result in a breach of the legislative decision
on limiting conditional approvals, confirmed in the context
of the pharmacovigilance legislation in 2010. Even if MAPPs
were limited to special cases, payers would need to actively
consider updates to the framework to optimize the managed
entry of new medicines in areas of high unmet need. This would
create considerable challenges within countries. Consequently,
earlier access even under the current legislative environment
harbors risks and should only be considered under exceptional
circumstances.
13“Adaptive licensing” or “adaptive pathways”: Deregulation under the
guise of earlier access. Available at URL: http://english.prescrire.org/Docu/
DOCSEUROPE/20151019_AdaptiveLicensing.pdf.
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Pitfalls of Post-authorisation Evidence
Generation—Ensuring Efficacy and
Effectiveness
Instigating MAPPs also means that more evidence is to be
gathered after marketing authorization. This is of concern since
it is often difficult to recruit patients for post authorization
studies7. Additional concerns with this approach have been
highlighted in a recent publication (Banzi et al., 2015). The
authors demonstrated that the obligations imposed by the EMA
for conditional approvals are typically fulfilled only with delay
and often incompletely, if ever, by pharmaceutical companies.
It has been said that ensuring the fulfillment of obligations like
post-approval evidence generation is one of the core issues to
be addressed in adaptive pathways, and that these obligations
will be legally binding. However, if there are already delays and
concerns with such schemes, it is difficult to see how this will
change especially with more medicines subject to this route.
Consequently, again we believe MAPPs should only apply to
areas where there is an agreement between all concerned parties
(including payers) that there is a true considerable unmetmedical
need that may be ameliorated without creating new problems and
that all the uncertainties with the new medicine have been fully
communicated and concerns with existing schemes addressed
(Hawkes, 2016a).
Stratification of the Use of a Medicine
Stratified medicines, especially fragmentation of populations and
better understanding of diseases, have been described as drivers
and enablers of adaptive pathways (Eichler et al., 2015). Stratified
medicine undoubtedly results in smaller treatment populations.
Due to these smaller populations, RCTs are seen by some as
unfeasible. We strongly dispute this in most situations given the
appreciable number of patients that exist across Europe within
the current definition for orphan diseases (Garattini, 2012),
and pharmaceutical research and development being planned
globally. On this scale, most potentially targeted populations
are big enough to support randomized trials as shown in a
recent study demonstrating randomisation in studies for new
medicines for orphan diseases (Picavet et al., 2013). This is
further supported by publications suggesting that a number of
medicines for orphan diseases have now reached blockbuster
status (Kesselheim et al., 2012).
Additionally, stratification promises to provide a population
where the chances of increased effectiveness in terms of reducing
the numbers needed to treat, or alternatively, increasing the
numbers needed to harm, are improved (Godman et al., 2013).
This should further improve the chances of showing clinically
relevant differences in relatively small trials.
Stratified medicine combined with better understanding of
diseases is supposed to open opportunities for extrapolation of
results from one population to another.
In this context, basket trials of patients with different diseases
harboring the same genomic aberration that is supposed to be
causative to their diseases have been exemplified as modern trial
designs fitting adaptive pathways (Redig and Janne, 2015). Payers
are wary of this especially if companies use small populations to
drive up requested prices14 (Godman et al., 2013). Even when
for example a specific cancer mutation has been shown to be
causative in some entities, response in other cancer entities
harboring the same mutation was not predictable (Hyman et al.,
2015). This clearly demonstrates the limits to the extent of
possible extrapolations during approval.
Limiting the Use of a Medicine to Specific
Patients—Prescription Control
We have explained our concern that early availability of
new, untested medicines, among the general population, which
typically exhibits greater co-morbidities and higher age than
the well-controlled population entered into phase II and III
clinical trials, may jeopardize patient safety (Joppi et al., 2013;
Malmstrom et al., 2013). In an environment where medicines
are approved for small, well defined populations early on
and evidence of their potential benefits and risks for a wider
population is to be generated after this approval, restricting the
use of these medicines is essential. This is why EMA’s report
emphasizes the need for prescription control4. However, it is left
very unclear how this is to be accomplished.
Limiting the use of medicines to approved populations is
challenging (Davis et al., 2016). Payers can limit reimbursement
for use of medicines outside approved populations; however,
enforcement of these restrictions can be difficult in a number
of European countries without specific regulations in place
(Godman et al., 2010). Any added costs and use of resources due
to unwarranted use ofmedicines outside of approved populations
will be a burden to payers especially if requested prices are higher
than current standards. Several member states also currently
do not provide a legal framework to limit doctors’ therapeutic
freedom, even if reimbursement may be excluded. However, this
is not universal.
Authorization of the use of medicines to approved
populations is not a valid reason for restricting their off-label use
where this is warranted on clinical grounds. Other mechanisms
exist, such as devolved budgets, physician education, 100%
co-payment for prescribing outside of agreed indications and
payback mechanisms. However, these can be labor-intensive and
costly to administer (Adamski et al., 2010; Godman et al., 2012a,
2014; Ferrario and Kanavos, 2013; Malmstrom et al., 2013).
EMA’s report on Adaptive Licensing acknowledges the necessity
of clear indications and we emphasize this point in this paper4.
Vague or ambiguous definitions of indications are not helpful,
e.g. when a new medicine is licensed for “patients for whom the
[standard of care] is not appropriate.”
MAPPs imply that medicines approved in limited populations
due to promising results of phase II trials are already being
further researched whilst being prescribed in clinical care. It is
important to repeat that this would further blur the boundary
between research and routine use, and that patients would need
to be informed about and accept this change (Husereau et al.,
2014). It is also important to point out that clinical trials in
14Secret des affaires, Autorisations de mise sur le marché au rabais et opacité
des essais cliniques. Available at URL: https://blogs.mediapart.fr/formindep/blog/
010415/secret-des-affaires-autorisations-de-mise-sur-le-marche-au-rabais-et-
opacite-des-essais-cliniques.
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populations for whom a medicine is already approved face
certain obstacles. Such patients, unlike volunteers in randomised
trials, may well not accept randomisation and blinding. Non-
randomized, observational trials are more vulnerable to biases
and they need to be designed even more meticulously than RCTs
to avoid false results. Even then, the validity of observational
trials is limited, compared to equally well designed, prospectively
planned, randomized trials. We would expect to see more
new medicines with unclear benefit-risk-assessments as MAPPs
progresses. Currently, it is unclear howmore data collected under
adaptive pathways can compensate the inherent flaws with such
approaches.
Implications for the Pricing of New
Medicines Including Negotiations
MAPPs aim to replace the so called “single magic moment”
of approval by progressive management (Eichler et al., 2012;
EMA15). From a payers’ point of view, theremaywell be instances
in which adaptive pathways are reasonable and necessary.
However, there are concerns that high prices eventually granted
for a targeted group of patients will be exploited when
the numbers of indications are expanded, with considerable
budgetary implications. One of the examples is ivacaftor, which
already causes concerns to payers with its high requested price
and comparatively limited patient benefits (Eichler et al., 2015;
Godman et al., 2015). We are also already seeing a number of
orphan medicines achieving “blockbuster” status as a result of
such exploitation (Kesselheim et al., 2012). Differential pricing
by indication is difficult for payers to cope with especially given
limited routine availability of patient level data among countries
and regions in Europe, MEAs difficult to administer and the
appreciable use of external reference pricing among European
countries (Adamski et al., 2010; Leopold et al., 2012; Ferrario and
Kanavos, 2013).
In a recent publication, the authors expressed the hope
that MAPPs might help to address the strain that high-priced
medicines put on healthcare systems (Eichler et al., 2016).
This can be disputed especially as the prices requested by
pharmaceutical companies for their new medicines rarely mirror
their development costs (Experts in Chronic Myeloid Leukemia,
2013). In addition, ever increasing prices are being charged for
new medicines despite only a small minority of them considered
as innovative by independent authorities (Kelly and Smith, 2014;
Godman et al., 2015; Howard et al., 2015). The majority of new
medicines are seen as similar or with marginal improvements
over existing standards (Godman et al., 2015; Prescrire Editorial,
2016). This is especially the case for new cancer medicines
despite similar development costs (Kantarjian et al., 2013).
However, cancer medicines are not an isolated case. The prices
of new medicines for hepatitis C have stimulated debates
over reimbursed prices especially where there are appreciable
differences between the costs of manufacture and requested
prices (Phelan and Cook, 2014; de Bruijn et al., 2016), especially
15Adaptive pathways to patients: report on the initial experience of the
pilot project. Available at URL: http://www.ema.europa.eu/docs/en_GB/
document_library/Report/2014/12/WC500179560.pdf.
when the latter threaten health care budgets and their viability
(Brennan and Shrank, 2014).
MEAs are an attempt to achieve risk sharing and flexible
approaches to reimbursement and are perceived as an integral
part of adaptive pathways that already involve payers. Currently,
MEAs are not legally feasible in all EU Member States.
Consequently, the need for this would result in an adjustment
of national legislations. In addition, MEAs are predominantly
in the control of pharmaceutical companies. As a result, they
control which Member States are involved as well as the different
conditions in Member States, depending on the Member State’s
power of negotiation (Ferrario and Kanavos, 2013). This leads
to a distorted market and significantly different levels of access
and affordability of new medicines for patients across Europe.
From a public health or societal perspective, this is unacceptable.
Apart from this, performance-based agreements under MEAs
bear high transaction and administrative costs and are not
easily implemented (Adamski et al., 2010; Ferrario and Kanavos,
2013, 2015). Adaptive pathways are not designed to lower these
hurdles, which further underlines the belief among payers that
they need to be low in number and limited to very special
cases. Consequently, adaptive pathways cannot be the preferred
approach for new medicines in the future.
Shifting of Research for New Medicines to
the Post-authorisation Phase—Who
Should Bear the Costs?
There also are concerns regarding who should fund any
additional costs to healthcare systems arising from higher
prices for a new medicine versus existing standards during
the conditional approval process as well as fund the data
collection process. This is because increasing the amount of
data generated post-licensing will result in a shift in costs.
In the current environment, pre-marketing clinical trials are
funded by pharmaceutical companies alone. If these costs are
shifted to payers or the public, pharmaceutical companies need
to come to an agreement with health authorities and health
insurance companies on how the increased costs to healthcare
systems will be compensated. Such costs include introducing
comprehensive IT systems where currently it is problematic to
collect comprehensive patient level data for the entire population.
Enforcement—What if it Doesn’t Work?
A central task in adaptive pathways will be to ensure that
exit strategies are in place for new medicines not fulfilling
expectations. No application should be complete without a full
description of what will happen if patients do not respond
to treatment. “No response” should be clearly defined in
terms of the hoped-for outcomes and the consequences for
all stakeholders. Revoking a marketing authorization has been
difficult in the past and we do not expect it to be any easier
in the future. This is no different for medicines approved with
a conditional approval which do not manage to proceed to
a standard approval. We have observed protests from doctors
and patients likewise, independent of whether a medicine has
been withdrawn or considered for withdrawal due to safety
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issues, lack of proven benefit or economic reasons (Raftery,
2010; Simoens et al., 2013). It has been indicated that rules
for withdrawal could be part of MEAs (Eichler et al., 2015).
In our experience, revoking a reimbursement decision can be
even more difficult than revoking a marketing authorization;
however the degree of difficulty depends on the local legal and
cultural environment. Consequently for MAPPs to be workable,
conditions for suspending marketing authorization of a new
medicine should be included as part of any adaptive licensing
process and decision. These should cover situations where there
is a worsening of the risk-benefit-balance as more data becomes
available and/ or where a company fails to generate the necessary
data within defined time frames to continue to support requested
prices. This process needs to be well-grounded in European law.
Responsibility and Liability for Uncertainty
and Possible Risk Factors
In the context of adaptive pathways, a prohibition of product
liability law suits during the initial marketing period has
been proposed (Eichler et al., 2012). We see this proposal
as unacceptable and not in line with European legislation. It
also contradicts the official position of EMA that the current
legislative framework is not to be changed. One cannot on
the one hand open the way to earlier commercialisation and
on the other hand transfer any risks arising from the new
medicine to patients and the public domain. This liability
prohibition exploits the special vulnerability of ill persons. This
is even more questionable in the context of discussions about
whether adaptively licensed products require even longer periods
of intellectual property protection6. Earlier commercialisation,
longer periods of exclusivity paired with reduced liability for
damages gravely unbalance the concept of adaptive pathways.
WAYS FORWARD/CONCLUSIONS
Managing the entry of new medicines is undoubtedly necessary
given the fact that a number of European countries are already
struggling to fund new medicines at ever increasing prices
(Malmstrom et al., 2013).
Whilst being open for constructive evaluation and dialogue on
how the process of new drug development and their introduction
can be improved, payers and their advisers have a number of
concerns regarding current MAPPs to accelerate drug approval.
This paper has aimed to describe these concerns and potential
problems that arise from a payer perspective. Potential ways
forward include developing newmodels to optimize themanaged
entry of new medicines as well as careful consideration which
new medicines are applicable for the adaptive licensing process
given existing procedures and concerns.
Suggested models for the introduction of new medicines
build on payer concerns when dabigatran was being launched
(Malmstrom et al., 2013; Permanand and Bak Pedersen, 2015).
This started with extensive activities to combat pre-launch
marketing in a number of countries. Payer concerns with
dabigatran included the potential for excessive bleeding in
elderly patients with atrial fibrillation with poor renal function,
which were echoed in the deliberations between the marketing
and medical departments of the company (Malmstrom et al.,
2013; Cohen, 2014). An additional basis for future payer
recommendations and involvement is also the constructive
dialogue with all key stakeholder groups surrounding the
development of pricing models for new medicines for orphan
diseases—The Transparent Value Framework (Godman et al.,
2015, European Commission16).
The introduction of new medicines into national health
services is a trade-off between efficacy, safety, certainty and cost.
Shifting the current balance to accelerate market access must
consider not only the potential benefits, but also the potential
harms to patients and society if a new medicine ultimately does
not perform as originally expected.
Models that have been developed for managing the
introduction of new medicines center on the three pillars
of pre-, peri- and post-launch (please see Malmstrom et al. for
further details). Pre-launch activities include horizon scanning
and budgeting activities to identify new medicines that could
have important implications for health services either in terms
of potential costs, potential concerns as seen with dabigatran,
or both. These can take place up to 3 years before potential
EMA approval (Joppi et al., 2009; Wettermark et al., 2010;
Godman et al., 2012b). Activities could also include educational
activities as well as the development of quality indicators for
use post launch. Peri-launch activities include all aspects of
valuing and funding new medicines including reimbursement
considerations as well as MEAs or risk-sharing arrangements
(Adamski et al., 2010; Ferrario and Kanavos, 2013; Paris and
Belloni, 2013). Post-launch activities include risk management
plans (RMPs) as well as monitoring the effectiveness and safety of
new medicines in routine clinical practice using electronic health
records, registries or other approaches as well as monitoring the
prescribing of medicines against agreed guidance and/ or quality
indicators (Campbell et al., 2015; Godman et al., 2016).
The current tools and procedures for the management of
new medicines would need to be further adapted and refined
to meet the requirement of MAPPs. This involves a number
of challenges including addressing the clarity of outcome
parameters used and the time-frames connected with conditional
approval and reimbursement. A redesign of the HTA process
might be necessary to mirror the changes in the lifecycle of
the products, particularly during the period of conditional
approval and in their transition to a marketing authorization
which is no longer conditional. Technologies for sophisticated
interrogation of health authority databases with patient level
data would be essential for the realization of concepts such as
MAPPs. Currently, the use of these technologies is fraught with
uncertainties and limitations.
EMA’s report indicates that a great deal of work needs to
be done to consistently ensure that any registries proposed for
the collection of clinical outcomes across countries are fit for
16Process on Corporate Social Responsibility in the Field of Pharmaceuticals
Platform on Access to Medicines in Europe Working Group on Mechanism
of Coordinated Access to Orphan Medicinal Products (MoCA-OMP) -
TRANSPARENT VALUE FRAMEWORK. Available at URL: http://ec.europa.eu/
enterprise/sectors/healthcare/files/docs/orphans_conlusions_en.pdf2012.
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purpose4. Many post-authorization drug registries are fraught
with potential biases. All too frequently data collection, data
analysis and data interpretation are in the hands of, or heavily
influenced by, the applicant. We have seen that this can lead to
potential bias compared to independent registries (Marra et al.,
2016). Consequently, requirements for balanced governance of
registries should be in place.
From the perspective of academics researching the rational
use of medicines, and from the perspective of payers and their
advisers, concerns with the key issues described in this paper
restricts the MAPPS pathway to medicines effectively addressing
high unmet medical need, where high unmet need is narrowly
defined.
It is not our intention as payers to create more barriers
to the availability of new medicines where there is unmet
medical need. However, payers need to make sure available funds
provide comprehensive and equitable healthcare in all European
countries and that one group of patients is not unfairly treated
to the detriment of others. We hope this paper will stimulate
important considerations and debates leading to developments to
allay payer’s concerns with adaptive pathways for new medicines.
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